deltatrials
Completed PHASE2 INTERVENTIONAL NCT00219817

Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

Sponsor: Helsinn Therapeutics (U.S.), Inc

Conditions Cancer Cachexia
Interventions RC-1291 HCl
Updated 5 times since 2017 Last updated: Aug 30, 2013 Started: Jun 30, 2005 Primary completion: Oct 31, 2006 Completion: Oct 31, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cancer Cachexia, this trial is completed. The trial is conducted by Helsinn Therapeutics (U.S.), Inc and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Helsinn Therapeutics (U.S.), Inc
Data source: Helsinn Therapeutics (U.S.), Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations